^
BIOMARKER:

CDKN2A mutation

i
Other names: CDKN2A, ARF, CDK4I, CDKN2, CMM2, INK4, INK4a, MLM, MTS1, p14, p14ARF, p16, p16INK4a, p19, p19Arf, Cyclin-dependent kinase inhibitor 2A
Entrez ID:
Related biomarkers:
CDKN2A mutation
Triple Negative Breast Cancer
atezolizumab
Sensitive: B - Late Trials
CDKN2A mutation
Breast Cancer
ribociclib
Resistant: B - Late Trials
CDKN2A mutation
Gallbladder Cancer
palbociclib
Resistant: C3 – Early Trials
CDKN2A mutation
Clear Cell Renal Cell Carcinoma
palbociclib
Sensitive: C3 – Early Trials
CDKN2A mutation
Pancreatic Cancer
palbociclib
Resistant: C3 – Early Trials
CDKN2A mutation
Solid Tumor
Immunotherapy
Resistant: C3 – Early Trials
CDKN2A mutation
Melanoma
Immunotherapy
Resistant: C3 – Early Trials
CDKN2A mutation
Urothelial Cancer
Immunotherapy
Resistant: C3 – Early Trials
CDKN2A mutation
Biliary Tract Cancer
toripalimab
Resistant: C3 – Early Trials
CDKN2A mutation
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
CDKN2A mutation
Penile Cancer
nivolumab
Sensitive: C4 – Case Studies
CDKN2A mutation
SCCHN
AZD1775 + VIC-1911
Sensitive: D – Preclinical
CDKN2A mutation
NSCLC
AZD1775 + VIC-1911
Sensitive: D – Preclinical
CDKN2A mutation
Melanoma
palbociclib
Sensitive: D – Preclinical